Eli Lilly's (LLY) CDO says the Co. plans to sustain its aggressive dealmaking pace in 2026, Axios reports
Context
Eli Lilly's commitment to maintain an aggressive dealmaking strategy signals a strong growth outlook and optimism in its pipeline. This could influence investor sentiment positively, not just for LLY but also for its peers in the pharmaceuticals sector, possibly leading to increased valuations and activity within the biotech and life sciences space.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#ELI LILLY & CO#LLY.US#EQUITIES#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES